S4-Oligo: optimizing polygenic score methods for clinical deployment
- 1Cedars Sinai Health Sciences University
Abstract
Polygenic scores (PGSs) have progressed toward clinical utility in recent years, demonstrating odds ratios that are comparable with both lifestyle-related and monogenic risk factors for several complex diseases. However, PGS implementation relies on developing analytically and clinically valid assays. Methods for developing polygenic models (PGMs) that incorporate tens of thousands to millions of variants require either genome-wide chip genotyping combined with imputation or whole genome sequencing, limiting their portability. Additionally, variants may be in regions where the local genomic sequence makes it difficult to assay, and multi-allelic or strand ambiguous variants can make bioinformatics more complicated. Because of these challenges, attempts to develop a reliable assay for published PGMs can produce multiple variations from the same underlying model, hindering routine clinical deployment and incorporation into multi-factorial risk prediction models. In this analysis, we present an adjustment to the previously published select and shrink with summary statistics (S4) PGM method designed to optimize performance for realistic clinical use by restricting to a pre-specified number of available SNPs that are well-captured by genotyping arrays. We compare the performance of this oligogenic S4 method (S4-Oligo) to currently published PGSs as well as the full S4 model for prediction of breast, colorectal, ovarian, and prostate cancers in the All of Us Research Program, Biobank Japan, and UK Biobank. We find that S4-Oligo matches or exceeds the accuracy of published PGMs at comparable model sizes while retaining between 88% and 99% of the performance of the original S4 model when limited to 1,000 variants.
Related
- Hybrid risk scores integrating polygenic and clinical variables for endometriosis prediction
- Clinical history shapes the predictive value of polygenic risk
- Polygenic risk scores for LATE-neuropathologic change: Implications for clinical utility.
- Context-Dependent FHIR Serialisation Strategies for Clinical LLM Deployment: A Multi-Layer Benchmark on UK Core Data
- Medico-legal integration of molnupiravir rapid deployment during the COVID-19 pandemic: Emergency use authorization, clinical evidence, and risk of viral mutagenesis
BibTeX
@misc{baierl2026s4oligo,
title = {{S4-Oligo: optimizing polygenic score methods for clinical deployment}},
author = {J. D. Baierl and J. P. Tyrer and D. R. Barnes and M. R. Jones and P.-C. Peng and M. Tischkowitz and A. C. Antoniou and P. D. P. Pharoah},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.16.26365773},
url = {https://www.medrxiv.org/content/10.64898/2026.10.16.26365773v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - S4-Oligo: optimizing polygenic score methods for clinical deployment
AU - J. D. Baierl
AU - J. P. Tyrer
AU - D. R. Barnes
AU - M. R. Jones
AU - P.-C. Peng
AU - M. Tischkowitz
AU - A. C. Antoniou
AU - P. D. P. Pharoah
PY - 2026
DA - 2026/10/16
PB - medRxiv
DO - 10.64898/2026.10.16.26365773
UR - https://www.medrxiv.org/content/10.64898/2026.10.16.26365773v1
AB - Polygenic scores (PGSs) have progressed toward clinical utility in recent years, demonstrating odds ratios that are comparable with both lifestyle-related and monogenic risk factors for several complex diseases. However, PGS implementation relies on developing analytically and clinically valid assays. Methods for developing polygenic models (PGMs) that incorporate tens of thousands to millions of variants require either genome-wide chip genotyping combined with imputation or whole genome sequencing, limiting their portability. Additionally, variants may be in regions where the local genomic sequence makes it difficult to assay, and multi-allelic or strand ambiguous variants can make bioinformatics more complicated. Because of these challenges, attempts to develop a reliable assay for published PGMs can produce multiple variations from the same underlying model, hindering routine clinical deployment and incorporation into multi-factorial risk prediction models. In this analysis, we present an adjustment to the previously published select and shrink with summary statistics (S4) PGM method designed to optimize performance for realistic clinical use by restricting to a pre-specified number of available SNPs that are well-captured by genotyping arrays. We compare the performance of this oligogenic S4 method (S4-Oligo) to currently published PGSs as well as the full S4 model for prediction of breast, colorectal, ovarian, and prostate cancers in the All of Us Research Program, Biobank Japan, and UK Biobank. We find that S4-Oligo matches or exceeds the accuracy of published PGMs at comparable model sizes while retaining between 88% and 99% of the performance of the original S4 model when limited to 1,000 variants.
ER -